The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals' Livsayis (cemdisiran) on November 18, 2026, marking the first siRNA therapy for generalized myasthenia gravis. Administered subcutaneously four times a year, Livsayis achieved a placebo-adjusted 2.3-point MG-ADL improvement in the Phase 3 NIMBLE trial. Concurrently, FDA approved AstraZeneca's weekly autoinjector Klygefa. Both C5-targeted treatments enter a competitive market alongside established therapies from argenx and UCB.
FDA approval and administration of Livsayis
- ▪Regeneron said Livsayis is administered by subcutaneous injection once every three months, making it the longest dosing interval among FDA-approved generalized myasthenia gravis treatments
- ▪The U.S. FDA approved Regeneron Pharmaceuticals' Livsayis (cemdisiran) on November 18, 2026, for adult patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
Mechanism and safety profile of Livsayis
- ▪The FDA prescribing information for Regeneron's Livsayis includes a Boxed Warning for serious meningococcal infections and requires access through a restricted Risk Evaluation and Mitigation Strategy program
- ▪Livsayis is a complement component factor 5 directed small interfering RNA therapeutic that degrades C5 messenger RNA to block C5 protein production
NIMBLE trial results for Livsayis
- ▪In the Phase 3 NIMBLE trial, 76.6 percent of Livsayis-treated patients achieved at least a 3-point MG-ADL score improvement at week 24 compared to 44.1 percent for placebo
- ▪In the Phase 3 NIMBLE trial, Livsayis demonstrated a placebo-adjusted 2.3-point improvement on the Myasthenia Gravis-Activities of Daily Living total score at 24 weeks
FDA approval and structure of Klygefa
- ▪The FDA approved AstraZeneca and Alexion's Klygefa (gefurulimab-gaks) on November 16, 2026, as a once-weekly self-injected C5 inhibitor for adult anti-acetylcholine receptor positive gMG patients
- ▪AstraZeneca's Klygefa is a dual-binding nanobody that combines an N-terminal albumin-binding domain with a C-terminal C5-binding domain to extend blood half-life and enable weekly dosing
PREVAIL trial results for Klygefa
- ▪In the Phase 3 PREVAIL trial, Klygefa-treated patients achieved a 4.5-point QMG total score improvement at week 26 compared to a 2.4-point improvement for placebo
- ▪In the Phase 3 PREVAIL trial of 260 patients, weekly Klygefa achieved a 1.6-point greater MG-ADL score reduction than placebo at week 26
Myasthenia gravis prevalence
- ▪Myasthenia gravis affects approximately 85,000 people in the United States, causing abnormal anti-acetylcholine receptor antibodies to activate complement protein C5 and damage the neuromuscular junction
- ▪An estimated 150 to 200 out of every million people worldwide have myasthenia gravis
Existing treatment landscape
- ▪Projected prescription data through September 30, 2026, showed argenx's Vyvgart leading generalized myasthenia gravis patient starts with about 3,138 starts
- ▪Existing C5-targeted generalized myasthenia gravis therapies include Alexion's Soliris and Ultomiris, argenx's Vyvgart, and UCB's Zilbrysq and Rystiggo
Story comments
Loading comments…